FCF YoY
+60.78%
OCF YoY
+52.65%
Capex YoY
-86.05%
FCF Conversion Δ
—
Free cash flow bridge for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $2.45B
FCF bridge breakdown for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$4.03B | — |
| Operating Cash Flow | $1.61B | +65.5% |
| Capital Expenditure | $845.00M | +34.5% |
| Free Cash Outflow | −$1.58B | — |
- Prior Free Cash Flow−$4.03B
- Operating Cash Flow$1.61B
- Capital Expenditure$845.00M
- Free Cash Outflow−$1.58B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement